Loading…
← CockpitCompetitor Analysis › 4886.T ASKA Pharmaceutical Holdings Co., Ltd.Open in the cockpit ↗

ASKA Pharmaceutical Holdings Co., Ltd.4886.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum neutral 42
Mkt cap
$354M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$1.03M
20-day average traded
Fwd P/E
12.9×
forward earnings
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
82 days
8 Feb 2027
Close · JPY¥2,125
1D-1.4%
1W-1.1%
1M+4.9%
3M+0.7%
6M-24.3%
YTD+4.3%
1Y+0.5%
ATR %2.7%
52w lowhigh30.2% off high

What ASKA Pharmaceutical does

Employees: 1,611

ASKA Pharmaceutical at a glance

Size ASKA Pharmaceutical (4886.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $354M, the 1250th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,125 on 18 Nov 2026.

Performance Over six months the shares fell 24.3%, against -22.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 10.9% over the last twelve months (peer median +1.0%).

Valuation It trades at 12.9× forward earnings against a peer median of 28.1× (2nd cheapest of 7).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 784886.T 76
Six months, rebased to 100: ASKA Pharmaceutical against the median of its 20 peers (local-currency closes).

ASKA Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a¥71.1B¥64.1B¥62.8B¥60.5B
Revenue growth—+11%+2%+4%—
Gross profitn/a¥34.1B¥31.3B¥30.7B¥28.6B
EBITDAn/a¥8.92B¥7.58B¥9.16B¥8.24B
Net income¥5.21B¥5.42B¥5.10B¥7.54B¥4.24B
Free cash flown/a¥3.75B-¥475M¥166M¥2.89B
Capital expendituren/a¥2.87B¥3.56B¥1.45B¥746M
Total debt¥9.91B¥11.4B¥10.9B¥9.48B¥12.6B

Quarterly statements and history in the cockpit →

ASKA Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%0%+50%+100%+150%0001536005944569UNICHEMLAB005690301111MPLTSPRYPBYISOLARAMYX4886.T6-month return →1-month return →
Up and to the right = strong over both horizons. ASKA Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%+50%0×200×400×4569005690PBYISOLARA187545524886.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ASKA Pharmaceutical is the large dot.

ASKA Pharmaceutical competitors and peer comparison

How ASKA Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ASKA Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4886.TPeer medianRank in peer set
1-month return+4.9%-9.8%2nd highest of 20
6-month return-24.3%-22.1%8th lowest of 20
Distance from 52-week high-30.2%-38.5%7th highest of 21
Revenue growth (TTM)+10.9%+1.0%4th highest of 19
Forward P/E12.9×28.1×2nd cheapest of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/a12.9×n/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%n/a3.6%+3.1%
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%n/a8.0%-11.3%
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%35.5×6.7%+4.2%
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%n/an/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%8.2×-7.9%+24.8%
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%n/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%n/an/an/a
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%n/a22.2%-15.7%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%n/an/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%19.0×0.1%+0.3%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%n/an/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%20.7×38.3%-3.2%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%288.2×n/an/a
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%n/a19.0%-0.9%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%n/a9.2%+6.5%
Opus Genetics IRDUnited States$379M-22%-46%-778%n/an/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%398.3×n/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%n/a-11.5%+10.3%

Questions

Which companies are ASKA Pharmaceutical's closest peers?
The cockpit's peer set: Anhui Fengyuan Pharmaceutical (000153.SZ), Guizhou Yibai Pharmaceutical (600594.SS), KYORIN Pharmaceutical (4569.T), Unichem Laboratories (UNICHEMLAB.NS), Tuoxin Pharmaceutical (301089.SZ), Pharmicell (005690.KS), Guangdong Lifestrong Pharmacy (301111.SZ), 6467 (6467.TW).
Is ASKA Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 12.9× against a peer median of 28.1×, 2nd cheapest of 7 in its peer set.
How has ASKA Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.3% against -22.1% for the median peer; over one year +0.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.